Luma Group | Activity | F4

Introducing F4 Champions, a new accelerator for founders at the earliest stage.F4 Champions for early-stage foundersEnrollment closesAugust 2Learn more

Team Portfolio Raise Champions Essays

F4/Luma Group/Activity

Luma Group Activity

Every public signal F4 has attached to this firm, with sources and cross-entity links.

Types

Time range

New Fund

Closed debut LumaBio Fund I at $410M, a 15-year vehicle to back biotechs from discovery through commercialization.

LumaBio Fund I

fiercebiotech.comSEP 9, 2026

SEP 9, 2026

Exit

Eli Lilly agreed to acquire Luma-co-founded Vaccine Company for up to $1.55B to advance its In Vivo Nanoparticle vaccine technology.

Vaccine Company

Vaccine Company Luma Group

prnewswire.comMAY 26, 2026

MAY 26, 2026

Investment

Joined Coultreon Biopharma's oversubscribed $125M Series A, led by Sofinnova with Forbion and Novo Holdings co-leading.

Coultreon Biopharma

Coultreon Biopharma Luma Group

globenewswire.comAPR 28, 2026

APR 28, 2026

Exit

Portfolio company Rome Therapeutics wound down and was acquired by Pretzel Therapeutics for undisclosed terms.

Rome Therapeutics

Rome Therapeutics Luma Group

fiercebiotech.comJAN 12, 2026

JAN 12, 2026

3 investments· SEP 2024 – OCT 2025Show all

Investment

Led Curve Biosciences' $40M Series A for its Whole-Body Intelligence chronic disease monitoring platform.

CurveBio

CurveBio Luma Group

businesswire.comOCT 29, 2025

OCT 29, 2025

Investment

Co-led Character Biosciences' $93M Series B alongside aMoon.

Character Bio

Character Bio Luma Group

seedtable.comMAR 25, 2025

MAR 25, 2025

Investment

Participated in Arsenal Biosciences' $325M Series C to advance programmable cell therapy programs.

Arsenal Bio

Arsenal Bio Luma Group

arsenalbio.comSEP 4, 2024

SEP 4, 2024